Document is current

Article History

Received: 24 June 2024

Accepted: 21 October 2024

First Online: 4 November 2024

Declarations

:

: This study has been approved by the ethics committee of the Second Affiliated Hospital of Wenzhou Medical University. And informed consent was obtained from all subjects involved in the study. The project was titled as “The establishment of a co-delivery Nano-granular system based on TRAIL-exosome, siRNA and cisplatin and its application in drug-resistant cervical cancer (No. 2016kykt31)”, and was approved on 03/10/2016. The animal experiments were in line with the regulations promulgated by the Institutional Animal Care and Use Committee of Wenzhou Medical University. The project was titled as “The mechanistic exploration of a novel biomimetic nanozyme based on TRAIL target for reversing radio-resistance of cervical cancer to synergistically improve immunotherapy (No. wydw2021-0176)”, and was approved on 03/10/2021. Shanghai Cell Biology Medical Research Institute and Shanghai BinSui Biological Technology Co. have confirmed that there was initial ethical approval for collection of human cells (SiHa, HeLa, ECT1), and that the donors had signed informed consent.

: Not applicable.

: The authors declare that they have no competing interests.